ProCE Banner Activity

Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: Analysis of Expert and Community Healthcare Provider Practice Trends


With new indications for immune checkpoint inhibitors (ICIs), treatment decisions for patients with locally advanced (LA) and metastatic urothelial carcinoma (mUC) are becoming increasingly complex. The aim of this analysis was to assess real-world practice patterns for LA or mUC and compare them with recommendations from US experts based on patient cases entered by healthcare providers (HCPs) into an online decision support tool designed to provide specific, individualized expert recommendations.

Released: February 15, 2019

Expiration: February 14, 2020


Additional Information

Tradd Sanderson
Director of Marketing
Clinical Care Options
Telephone: 855.224.2241